Gene therapy company Prevail raises $50M series B

Prevail raised $50 million in a series B round to advance its pipeline of gene therapies for neurodegenerative diseases.

Existing investors participating in the round included OrbiMed Advisors, Pontifax, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners, Boxer Capital, Adage Capital Management and Alexandria Venture Investments. New investors Surveyor Capital and AbbVie Ventures also invested...